|Clinical and Regulatory|
|Event Type:||Phase 2 Results|
|Designation(s):||Fast Track, Orphan Drug|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|Disease and Treatment|
|Indication:||Renal Cell Carcinoma|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
Mr. Guiffre continued, "The rate of disease progression in patients appears to have slowed down recently in our blinded trial of CRLX101 in combination with Avastin® (bevacizumab) in relapsed renal cell carcinoma (RCC); accordingly, we now expect top-line results in the third quarter 2016."